Medifast (NYSE:MED) Issues FY 2026 Earnings Guidance

Medifast (NYSE:MED) updated its FY 2026 earnings guidance on Monday morning. The company provided EPS guidance of -1.750–0.250 for the period, compared to the consensus estimate of -1.870. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $281.0 million. Medifast also updated its Q3 2026 guidance to -0.650–0.150 EPS.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MED shares. Weiss Ratings restated a “sell (e+)” rating on shares of Medifast in a research note on Monday. Zacks Research raised shares of Medifast from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $12.00.

Medifast Trading Up 34.7%

Shares of MED opened at $13.12 on Wednesday. The firm has a market cap of $145.86 million, a P/E ratio of -7.17 and a beta of 0.65. Medifast has a 12 month low of $9.22 and a 12 month high of $15.11. The stock’s 50 day moving average is $11.06 and its two-hundred day moving average is $11.05.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. The firm had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.63%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Equities research analysts forecast that Medifast will post -1.97 EPS for the current year.

Insider Buying and Selling

In other news, Director Scott Schlackman acquired 2,500 shares of the business’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the purchase, the director owned 30,549 shares in the company, valued at approximately $382,778.97. This represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in shares of Medifast by 103.1% in the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after buying an additional 1,187 shares during the last quarter. Quantbot Technologies LP purchased a new position in Medifast in the 3rd quarter worth approximately $37,000. Intesa Sanpaolo Wealth Management acquired a new position in shares of Medifast during the 4th quarter worth approximately $47,000. State of Wyoming acquired a new position in shares of Medifast during the 4th quarter worth approximately $59,000. Finally, Strs Ohio purchased a new stake in shares of Medifast in the first quarter valued at approximately $78,000. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.